Trial Profile
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Paclitaxel
- Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms GeparDouze
- 19 Mar 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.
- 19 Mar 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 04 Oct 2021 Status changed from recruiting to active, no longer recruiting.